STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Sera Prognostics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing reports a proposed sale of 6,447 Class A Common shares of Sera Prognostics (SERA) through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $16,377. The record lists 38,061,868 shares outstanding. The securities were acquired via restricted stock unit vesting from the issuer on 08/08/2025, with the same date shown as the approximate sale date.

The filing also discloses sales in the past three months by Benjamin Jackson: 7,084 shares sold on 05/08/2025 for $17,303 and 965 shares sold on 06/10/2025 for $1,433. Several standard filer contact fields (CIK/CCC and named account fields) are not populated in the provided content.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Form 144 notice for a small RSU-derived sale; amounts are immaterial to overall share count.

The filing documents a proposed sale of 6,447 shares valued at $16,377, against 38,061,868 shares outstanding, representing roughly 0.017% of the outstanding stock. Prior three-month disposals total 8,049 shares for $18,736. These figures indicate small, routine insider liquidity rather than a material equity shift. The filing provides transaction dates, broker details, and vesting provenance (RSU vesting), supporting compliance and transparency.

TL;DR: The notice is a standard compliance disclosure showing RSU vesting and planned sales; governance disclosure appears complete for Rule 144 purposes.

The form identifies the broker (Morgan Stanley Smith Barney), acquisition method (Restricted Stock Unit Vesting on 08/08/2025), and prior sales by Benjamin Jackson in May and June 2025 with gross proceeds. While some filer header fields are blank in the provided extract, the core Rule 144 sale and acquisition details are present, fulfilling the primary disclosure requirements for proposed insider sales.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the SERA Form 144 report?

The Form 144 reports a proposed sale of 6,447 Class A Common shares of Sera Prognostics via Morgan Stanley Smith Barney on 08/08/2025, aggregate market value $16,377.

How were the securities acquired according to the filing?

The securities were acquired by Restricted Stock Unit (RSU) vesting from the issuer on 08/08/2025, amount 6,447 shares.

Who sold shares in the past three months per the filing?

Benjamin Jackson is listed as selling 7,084 shares on 05/08/2025 for $17,303 and 965 shares on 06/10/2025 for $1,433.

How many SERA shares are outstanding as shown in the filing?

The filing shows 38,061,868 shares outstanding.

Which broker is named for the proposed sale in the Form 144?

The broker named is Morgan Stanley Smith Barney LLC, 1 New York Plaza, New York, NY.
Sera Prognostics, Inc.

NASDAQ:SERA

SERA Rankings

SERA Latest News

SERA Latest SEC Filings

SERA Stock Data

130.45M
33.40M
10.8%
64.96%
1.88%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY